YOKNEAM, Israel, Sept. 5, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in September:
Baird Healthcare Conference
Presenters: Yair Malca, Chief Financial Officer and Dr. Spero Theodorou, Chief Medical Officer
Format: In-person fireside chat moderated by Jeff Johnson, Senior Equity Analyst, and one-on-one meetings
Location: New York, NY
When: Tuesday, Sept. 12 at 11:25 am ET
A live webcast of the presentation can be accessed here.
Piper Sandler Aesthetics Day
Presenters: Yair Malca, Chief Financial Officer, Wanda Cummings, RN and Vice President of Clinical Operations, North America and Dr. Christopher Chia, double board-certified Plastic Surgeon and Surgical Director of bodySCULPT
Format: In-person investor bus tour and demo at bodySCULPT, an InMode certified plastic and cosmetic surgery center in NYC
Location: New York, NY
When: Wednesday, Sept. 27 at 1:00 pm ET
Cantor Global Healthcare Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Ross Osborn, Senior Equity Analyst, and one-on-one meetings
Location: New York, NY
When: Thursday, Sept. 28 at 10:55 am ET
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
| Last Trade: | US$17.91 |
| Daily Volume: | 619,484 |
| Market Cap: | US$1.370B |
September 04, 2024 August 06, 2024 July 31, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
